Research programme: slow off-rate modified aptamers - SomaLogic/Otsuka
Alternative Names: SL1026; SOMAmer®Latest Information Update: 28 Dec 2022
At a glance
- Originator SomaLogic
- Developer Otsuka Pharmaceutical; SomaLogic
- Class Nucleotide aptamers; Peptide aptamers
- Mechanism of Action Interleukin 6 inhibitors; Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis